AZD 4750

Drug Profile

AZD 4750

Alternative Names: AZD4750

Latest Information Update: 06 May 2005

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 21 Mar 2005 Discontinued - Phase-I for Multiple sclerosis in Sweden (unspecified route)
  • 29 Jan 2004 Phase-I clinical trials in Multiple sclerosis in Sweden (unspecified route)
  • 06 May 2003 Preclinical trials in Multiple sclerosis in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top